Intech Investment Management LLC Takes $1.06 Million Position in Hims & Hers Health, Inc. (NYSE:HIMS)

Intech Investment Management LLC purchased a new position in shares of Hims & Hers Health, Inc. (NYSE:HIMS) in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm purchased 57,774 shares of the company’s stock, valued at approximately $1,064,000.

A number of other hedge funds and other institutional investors have also bought and sold shares of HIMS. Nisa Investment Advisors LLC boosted its stake in shares of Hims & Hers Health by 679.2% during the 2nd quarter. Nisa Investment Advisors LLC now owns 1,839 shares of the company’s stock worth $37,000 after acquiring an additional 1,603 shares during the period. Quest Partners LLC lifted its holdings in Hims & Hers Health by 5,944.1% during the 2nd quarter. Quest Partners LLC now owns 3,566 shares of the company’s stock valued at $72,000 after purchasing an additional 3,507 shares during the last quarter. Van ECK Associates Corp bought a new position in Hims & Hers Health during the second quarter worth $111,000. CWM LLC increased its holdings in shares of Hims & Hers Health by 21.4% in the third quarter. CWM LLC now owns 5,982 shares of the company’s stock valued at $110,000 after purchasing an additional 1,054 shares during the last quarter. Finally, Amalgamated Bank raised its position in shares of Hims & Hers Health by 55.9% in the second quarter. Amalgamated Bank now owns 6,566 shares of the company’s stock valued at $133,000 after purchasing an additional 2,354 shares during the period. Institutional investors own 63.52% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages recently commented on HIMS. Bank of America downgraded shares of Hims & Hers Health from a “buy” rating to an “underperform” rating and reduced their target price for the stock from $32.00 to $18.00 in a report on Thursday, November 14th. Deutsche Bank Aktiengesellschaft increased their target price on Hims & Hers Health from $23.00 to $27.00 and gave the stock a “hold” rating in a research note on Wednesday, November 6th. Imperial Capital downgraded Hims & Hers Health from an “outperform” rating to an “in-line” rating in a research note on Friday, August 9th. TD Cowen reiterated a “buy” rating and set a $28.00 price objective on shares of Hims & Hers Health in a research report on Wednesday, November 20th. Finally, Canaccord Genuity Group boosted their target price on shares of Hims & Hers Health from $24.00 to $28.00 and gave the company a “buy” rating in a research report on Tuesday, November 5th. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating and seven have issued a buy rating to the company’s stock. Based on data from MarketBeat, Hims & Hers Health presently has a consensus rating of “Hold” and an average price target of $20.71.

Insider Activity

In other news, insider Soleil Boughton sold 2,345 shares of the stock in a transaction on Tuesday, September 3rd. The stock was sold at an average price of $14.65, for a total value of $34,354.25. Following the completion of the transaction, the insider now directly owns 159,796 shares in the company, valued at approximately $2,341,011.40. This represents a 1.45 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Oluyemi Okupe sold 269,739 shares of the business’s stock in a transaction on Monday, October 14th. The stock was sold at an average price of $20.31, for a total value of $5,478,399.09. Following the sale, the chief financial officer now owns 145,763 shares in the company, valued at $2,960,446.53. This represents a 64.92 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 1,153,519 shares of company stock worth $24,486,721. Corporate insiders own 17.71% of the company’s stock.

Hims & Hers Health Trading Down 1.1 %

NYSE HIMS opened at $30.35 on Thursday. The firm’s 50 day simple moving average is $21.14 and its 200 day simple moving average is $19.57. Hims & Hers Health, Inc. has a 1 year low of $8.09 and a 1 year high of $35.02. The firm has a market capitalization of $6.63 billion, a price-to-earnings ratio of 68.98 and a beta of 1.06.

Hims & Hers Health (NYSE:HIMS) last announced its quarterly earnings data on Monday, November 4th. The company reported $0.32 earnings per share for the quarter, topping the consensus estimate of $0.06 by $0.26. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. The business had revenue of $401.56 million during the quarter, compared to the consensus estimate of $382.20 million. During the same period in the prior year, the company earned ($0.04) EPS. Hims & Hers Health’s revenue for the quarter was up 77.1% on a year-over-year basis. On average, equities research analysts forecast that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current year.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.